- Home
- SWTX vs SNRE Comparison
SWTX vs SNRE Comparison
Compare SWTX & SNRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- SNRE
- Stock Information
- Founded
- SWTX 2017
- SNRE 2000
- Country
- SWTX United States
- SNRE Switzerland
- Employees
- SWTX N/A
- SNRE N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- SNRE Cable & Other Pay Television Services
- Sector
- SWTX Health Care
- SNRE Telecommunications
- Exchange
- SWTX Nasdaq
- SNRE Nasdaq
- Market Cap
- SWTX 3.5B
- SNRE 3.7B
- IPO Year
- SWTX 2019
- SNRE N/A
- Fundamental
- Price
- SWTX $46.67
- SNRE $51.28
- Analyst Decision
- SWTX Buy
- SNRE
- Analyst Count
- SWTX 7
- SNRE 0
- Target Price
- SWTX $56.86
- SNRE N/A
- AVG Volume (30 Days)
- SWTX 4.9M
- SNRE 188.1K
- Earning Date
- SWTX 05-09-2025
- SNRE 05-19-2025
- Dividend Yield
- SWTX N/A
- SNRE 7.35%
- EPS Growth
- SWTX N/A
- SNRE N/A
- EPS
- SWTX N/A
- SNRE N/A
- Revenue
- SWTX $219,670,000.00
- SNRE $3,386,277,504.00
- Revenue This Year
- SWTX $79.29
- SNRE N/A
- Revenue Next Year
- SWTX $70.79
- SNRE N/A
- P/E Ratio
- SWTX N/A
- SNRE N/A
- Revenue Growth
- SWTX 730.42
- SNRE N/A
- 52 Week Low
- SWTX $28.21
- SNRE $42.51
- 52 Week High
- SWTX $62.00
- SNRE $54.96
- Technical
- Relative Strength Index (RSI)
- SWTX 60.85
- SNRE N/A
- Support Level
- SWTX $46.21
- SNRE N/A
- Resistance Level
- SWTX $46.77
- SNRE N/A
- Average True Range (ATR)
- SWTX 0.15
- SNRE 0.00
- MACD
- SWTX -0.05
- SNRE 0.00
- Stochastic Oscillator
- SWTX 85.71
- SNRE 0.00
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
About SNRE Sunrise Communications AG American Depositary Shares representing Class A shares
Sunrise Communications AG is a telecommunications company. The company provides high-quality mobile, landline, broadband, and TV services to residential customers. The company also offers business customers 360-degree communications solutions and integrated ICT solutions for connectivity, security, and IoT from a single source to take companies forward in their quest for digitalization. It has three reportable segments being Residential customers; Business customers and Wholesale and Infrastructure and Support functions.